Koyfin Home > Directory > Health Care > Incyte Corp

Incyte Corp Price Chart INCY

Historical daily share price chart and data for Incyte Corp since 1993 adjusted for splits and dividends. The latest closing price for Incyte Corp as of August 03, 2020 is $101.79.
  • In 2020 the stock opened at $86.91 and closed at $101.79 for a gain of 15% YTD.
  • In 2019 the stock opened at $62.49 and closed at $87.32 for a gain of 28%.
  • In 2018 the stock opened at $97.36 and closed at $63.59 for a loss of -53%.
  • In 2017 the stock opened at $101.14 and closed at $94.71 for a loss of -7%.
View Chart On Koyfin

Incyte Corp Summary

Stock Symbol: INCY

Incyte Corp Company Info

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
660.52 %
30D Volatility
Hedge Fund Held
22.09 %

Last 10 Days of INCY Prices